PERSONAL INFORMATION

Giuseppe Viglietto

Director, Dipartimento di Medicina Sperimentale e Clinica (DMSC), Magna Graecia University, Catanzaro (I)

+39 0961 369 4281 [redacted]

viglietto@unicz.it

https://scholar.google.it/citations?user=VE0p9PQAAAAJ&hl=it

[redacted]

Enterprise	University	EPR
☐ Management Level	☒ Full professor	☐ Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator

WORK EXPERIENCE

From November 2017	Director, Dipartimento di Medicina Sperimentale e Clinica, Magna Graecia University, Catanzaro
From 2017 to 2020	President, Academic Senate, Magna Graecia University, Catanzaro
From 2012 to 2017	Scientific Director, Centro Servizi Genomica, Magna Graecia University, Catanzaro
From December 2004	Full Professor of General Pathology, Director of the Laboratory of Molecular Oncology at Dipartimento di Medicina Sperimentale e Clinica, Magna Graecia University, Catanzaro
2001- 2004	Researcher National Research Counsil of Italy (CNR IEOS), Naples
1992-2001	Staff Biologist, IRCCS "Fondazione G Pascale", Naples

EDUCATION AND TRAINING

1987	Degree in Biological Sciences, University Federico II, Napoli (110/110L)
1991-1994	Residency in Medical Genetics, University La Sapienza, Roma (70/70L)

RESEARCH ACTIVITY

The research activity of prof. Giuseppe Viglietto is documented by the publication of more than 140 manuscripts with 'peer review' in prestigious international journals (EMBOJ, PNAS, Am J Hum Gen, Oncogene, Cancer Res, JCI, Nature Med, Am J Path), seminars as well as from the acquisition of funding for research activities from public and private foundations.

Main scientific contribution of Prof. Viglietto:

i) cloning of the G6PD gene and molecular characterization of variants (Nucleic Acid Res 1985; EMBOJ 1986; Human Genetics 1989); ii) cloning and characterization of the endothelial growth factor PlGF (PNAS, 1991, Oncogene 1994, Lab Inv 1996); iii) molecular mechanisms that regulate tumor angiogenesis (Oncogene 1995; Oncogene 1997; Oncogene 1999); iv) molecular mechanisms of thyroid carcinogenesis (Oncogene 1995; JCI 1999; Cancer Res 2001; Oncogene 2003; Carcinogenesis 2005; Endocrine-related cancer 2007); v) inactivation of CDK inhibitors in cancer (Nature Medicine 2002; Cell Cycle 2004; Am J

Path 2005; Carcinogenesis. 2005; Cell Cycle 2007; Cell Cycle 2012); vi) identification of a new susceptibility gene for sporadic thyroid cancer (Endocrine-related Cancer 2010) or responsible for MEN4 syndrome (European J Endocrinology 2011); vii) identification of a new driver gene in lung cancer (Cell Cycle 2008; Cell Cycle 2009; Am J Path 2010; Am J Path 2011; PlosOne 2012; Oncotarget 2015; J Cancer. 2017; Oncotarget 2017; PlosOne 2017); viii) genetic characterization of ovarian (PlosOne 2013; Transl Oncol. 2021) and colorectal cancers (Oncotarget 2018; J. Exper. Clin Cancer Res 2018; Mol Cancer Res 2018); ix) generation of mouse models of disease (PlosOne 2016; Mol Cancer Ther. 2019); x) role of noncoding RNAs in cancer (RNA Biol. 2017; Cancer Res. 2017; Cell Death Dis. 2018; Noncoding RNA 2020; Cancers 2020).

GRANTS
2012-21

AIRC IG Codice Riferimento: 12969 (2012-2014); MIUR-PRIN prot. 2010W4H4RM_001 (2010-11); MIUR-PON R&C 2007-13, Project PON01_02782; MIUR-PON R&C 2007-2013, Project PON03a_00234; MIUR-PON R&C 2007-2013, Project PON03a_00435; MIUR-PRIN prot. 2017XJ38A4 (2017); MIUR-PRIN prot. 20209KY3Y7_003 (2020).

CLINICAL ACTIVITY

2013-2014 Director of the diagnostic program "Molecular Diagnostic in Oncology" at Fondazione Tommaso Campanella, Catanzaro.

2018-2022 Director of the diagnostic program "Molecular Diagnostic in Oncology" at AOU "Mater Domini", Catanzaro

ADDITIONAL INFORMATION

Publications

Total number of publications in peer-review journals: 132
Total Impact Factor (IF): 961.013; (average IF/paper): 7.28
Total number of citations: 8673; H index: 51

1. De Marco C et al., *Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancer*. Transl Oncol. 2021 Mar;14(3):101013.
2. De Marco C et al., *The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo*. Mol Cancer Ther. 2019 Feb;18(2):482-493.
3. Biamonte F et al. *Ferritin heavy subunit enhances apoptosis of non-small cell lung cancer cells through modulation of miR-125b/p53 axis*. Cell Death Dis. 2018 Dec 5;9(12):1174.
4. Mendes Oliveira D et al., *Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene*. J Exp Clin Cancer Res. 2018 Apr 17;37(1):84.
5. Conley et al., *High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients*. RNA Biol. 2017 Mar 4;14(3):305-316.
6. Scrima M et al. *Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients*. J Cancer. 2017 Jan 15;8(2):227-239.

Catanzaro, 28 gennaio 2022

[redacted]